AbbVie and Capsida Biotherapeutics expand their collaboration to develop genetic medicines for eye diseases
AbbVie and Capsida Biotherapeutics Inc. announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs.
The collaboration builds upon the neurodegenerative disease partnership announced in 2021. "This expanded collaboration with Capsida has the potential to develop transformative therapies for patients with serious eye diseases," said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research, AbbVie. "In pursuing the promise of genetic medicine-based therapeutics, AbbVie continues to expand our capabilities, and we are pleased to have Capsida as a partner."
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
